FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey

Inclusion Criteria: * Patients with treatment-resistant schizophrenia currently being treated with Clozaril or generic clozapine for at least 3 months * Patients with treatment-resistant schizophrenia who failed to respond adequately to treatment with at least 2 courses of standard drug treatments for schizophrenia, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs * Males and females of 18 years of age or older * Females of childbearing potential using a reliable form of contraception * Ability to comply with the required WBC/ANC monitoring schedule * Ability to follow physician's instructions * Signed informed consent by patient or legal guardian Exclusion Criteria: * Phenylketonurics * Females of childbearing potential not using a reliable form of contraception * Women who are pregnant or want to become pregnant * Nursing * Patients allergic to clozapine or any othe ingredient contained in FazaClo tablets * Patients who have previously experienced a severe adverse reaction to clozapine * Patients previously excluded from taking clozapine due to a higher risk of developing white blood cell disorders * Clinical significant medical condition that the physician believes may increase the patient's risk of participating int he study (e.g., severe cardiac disorder, epilepsy) * Concomitant medications that may be contraindicated with FazaClo * Patients who have been taking FazaCLo within the last three months * Patients unable to comply with the required WBC/ANC monitoring schedule * Patients unable to follow the physician's instructions * Patients unable or unwilling to provide Informed Consent